OKYO Pharma Limited Update on Placing to raise GBP560,000 (1165H)
March 23 2020 - 3:00AM
UK Regulatory
TIDMOKYO
RNS Number : 1165H
OKYO Pharma Limited
23 March 2020
FOR IMMEDIATE RELEASE
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH
JURISDICTION
23 March 2020
OKYO Pharma Limited
("OKYO" or the "Company")
Update on Placing to raise GBP560,000
Further to the Company's announcement of 19 March 2020 that it
had conditionally placed 112,000,000 new ordinary shares of no par
value in the Company (the "Placing Shares") at a placing price of
0.5 pence each (the "Placing Price") to raise GBP560,000 (before
expenses) (the "Placing"), the Company has agreed to stagger the
Placing into two tranches.
In light of an issue of shares on 22 May 2019 and, accordingly,
in order to avoid the need to publish a prospectus for the Placing,
the Company, with the agreement of the places, will now seek
Admission of 75,825,130 Placing Shares immediately, and make
further applications to the FCA and to the London Stock Exchange
for Admission of the balance of 36,174,870 Placing Shares for
admission on or about 25 May 2020.
The terms and conditions of the Placing are unchanged in all
other respects.
It is expected that Admission will become effective, and that
dealings in the first tranche of 75,825,130 Placing Shares are
expected to commence, at 8.00 a.m. on 24 March 2020.
The rights attaching to the Placing Shares will be uniform in
all respects and all of the Placing Shares will rank pari passu,
and form a single class for all purposes with, the existing issued
shares of no par value in the Company.
Following Admission of the Placing Shares, the enlarged Share
Capital will be 636,297,049 ordinary shares of no par value.
The Company will make a further announcement upon the closing of
the second tranche of the Placing.
The person who arranged for the release of this announcement on
behalf of the Company was Tiziano Lazzaretti, Chief Financial
Officer of OKYO.
About OKYO
OKYO Pharma Limited (LSE: OKYO) is a life sciences and
biotechnology company admitted to listing on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the Main Market for listed securities of the London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7382 8300
Antonio Bossi
Shore Capital Limited (Broker) David Coaten +44 (0)20 7601 6100
For further information, please visit the Company's website at
www.okyopharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEFLFIAVSIFFII
(END) Dow Jones Newswires
March 23, 2020 03:00 ET (07:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From May 2023 to May 2024